Cure8 trial brief
Mapping microbes and metabolites directly from different gut regions could reveal location-specific changes linked to IBD activity and help researchers develop better biomarkers or targeted treatments.
Demonstrating a safe, noninvasive sampling tool for IBD patients would also enable more precise microbiome research than stool alone.
Adult IBD patients (Crohn's and ulcerative colitis), gastroenterology clinicians and researchers interested in the gut microbiome and biomarker development, and people tracking innovations in minimally invasive gut sampling.
This is a prospective, single-center observational cohort planned to enroll 250 participants split across active and remission Crohn's and ulcerative colitis groups plus healthy controls.
Participants will swallow small sampling capsules that take fluid from four sites (upper jejunum, upper ileum, terminal ileum, and colon); saliva and stool will also be collected. Samples will be frozen and analyzed by sequencing and metabolomics at a specialized lab.
The study includes screening with a standard capsule endoscopy to reduce the risk of obstruction and follows participants for safety checks after capsule passage. Logistics and limitations: The study excludes people with strictures, fistulas, recent antibiotics, pregnancy, or major organ disease, so findings may not apply to those groups.
The capsule has prior small-sample safety testing but this trial will specifically assess feasibility and safety in IBD patients. The record describes planned methods and aims (trial-record), not results.
This is a registered observational study (not yet recruiting at time of record) describing planned enrollment, sampling methods, and laboratory analyses. The record reports study design and objectives rather than results; interpret accordingly.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Dietary components and processed vegetarian/vegan products may alter the gut microbiome and intestinal barrier — both are relevant to IBD. This study will directly compare common vegan products and meat substitutes with...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
